- Conditions
- Hemophilia A
- Interventions
- PEGylated Recombinant factor VIII (rFVIII)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- Gainesville, Florida • Peoria, Illinois • Louisville, Kentucky + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 1,383
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
- Interventions
- Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
- Interventions
- Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide
- Drug
- Lead sponsor
- Paolo Caimi, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
- Interventions
- Fludarabine, Clofarabine, Busulfan, Thymoglobulin, Stem Cell Infusion, Tacrolimus, Methotrexate
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 3 Years to 70 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
- Interventions
- Nemtabrutinib
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
- Interventions
- cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Interventions
- Angiotensin 1-7, Saline solution
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Tucson, Arizona
- Conditions
- Diabetes Mellitus
- Interventions
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Romidepsin
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Rancho Mirage, California • Santa Barbara, California + 9 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Abatacept Injection [Orencia] and Proleukin (aldesleukin)
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- erlotinib, RAD001
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Leukemia, Acute Myeloid, Leukemia, Lymphoblastic,Acute, Myelodysplastic Syndromes
- Interventions
- brentuximab vedotin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Protein Metabolism
- Interventions
- Protease + Protein, Placebo + Protein
- Dietary Supplement
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Lymphatic Diseases, Lymphatic Abnormalities
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 1 Day to 100 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib, Venetoclax, Rituximab
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 803 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • San Diego, California • San Francisco, California + 25 more
- Conditions
- Metastatic Cancer, Renal Cancer
- Interventions
- Atezolizumab, Bevacizumab, Entinostat
- Drug
- Lead sponsor
- Roberto Pili
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania
- Conditions
- Melanoma
- Interventions
- trametinib, nab-paclitaxel
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
- Conditions
- Carcinoid Tumor
- Interventions
- Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
- Drug
- Lead sponsor
- CASI pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
- Interventions
- Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP)
- Biological · Drug · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bipolar I Disorder, Schizoaffective Disorder, Psychosis
- Interventions
- Ketogenic diet
- Other
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Smoking Cessation, Weight Gain
- Interventions
- Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Pain
- Interventions
- anakinra, Placebo, Nociceptive pain challenge
- Drug · Other
- Lead sponsor
- Alan Prossin
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Pembrolizumab, Enzalutamide
- Drug
- Lead sponsor
- Mark Garzotto, MD
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Healthy Female Participants
- Interventions
- Navlimetostat, [14C]Navlimetostat
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin